Investors in Nuvation Bio Inc. (NYSE:NUVB) had a good week, as its shares rose 8.1% to close at US$4.81 following the release of its first-quarter results. In addition to smashing expectations with revenues of US$83m, Nuvation Bio delivered a surprise statutory profit of US$0.01 per share, a notable improvement compared to analyst expectations of a loss. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

Taking into account the latest results, the consensus forecast from Nuvation Bio's ten analysts is for revenues of US$200.4m in 2026. This reflects a sizeable 40% improvement in revenue compared to the last 12 months. Losses are supposed to decline, shrinking 16% from last year to US$0.35. Before this latest report, the consensus had been expecting revenues of US$190.2m and US$0.48 per share in losses. So it seems there's been a definite increase in optimism about Nuvation Bio's future following the latest consensus numbers, with a very favorable reduction to the loss per share forecasts in particular.

It will come as no surprise to learn thatthe analysts have increased their price target for Nuvation Bio 6.7% to US$12.33on the back of these upgrades. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. The most optimistic Nuvation Bio analyst has a price target of US$20.00 per share, while the most pessimistic values it at US$7.00. We would probably assign less value to the analyst forecasts in this situation, because such a wide range of estimates could imply that the future of this business is difficult to value accurately. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates.

Of course, another way to look at these forecasts is to place them into context against the industry itself. We would highlight that Nuvation Bio's revenue growth is expected to slow, with the forecast 57% annualised growth rate until the end of 2026 being well below the historical 98% p.a. growth over the last five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 8.8% per year. Even after the forecast slowdown in growth, it seems obvious that Nuvation Bio is also expected to grow faster than the wider industry.

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.

With that in mind, we wouldn't be too quick to come to a conclusion on Nuvation Bio. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for Nuvation Bio going out to 2028, and you can see them free on our platform here..

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.